Role of Cyclosporine (CsA) in Immuno-dermatological Conditions

Murlidhar Rajagopalan; Abir Saraswat; Byalakere Shivanna Chandrashekar; Sandipan Dhar; Sunil Dogra; Sushil Tahiliani; Praveen Raj

doi:10.4103/idoj.idoj_189_22

Role of Cyclosporine (CsA) in Immuno-dermatological Conditions

Indian Dermatol Online J. 2022 Sep 5;13(5):585-599. doi: 10.4103/idoj.idoj_189_22. eCollection 2022 Sep-Oct.

Authors

Murlidhar Rajagopalan¹, Abir Saraswat², Byalakere Shivanna Chandrashekar³, Sandipan Dhar⁴, Sunil Dogra⁵, Sushil Tahiliani⁶, Praveen Raj⁷

Affiliations

¹ Department of Dermatology, Apollo Hospital, Chennai, Tamil Nadu, India.
² Department of Dermatology, Indushree Skin Clinic, Lucknow, Uttar Pradesh, India.
³ Department of Dermatosurgery, CUTIS Academy of Cutaneous Sciences, Bengaluru, Karnataka, India.
⁴ Department of Pediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India.
⁵ Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
⁶ Dr. Sushil Tahiliani Clinic and P D Hinduja National Hospital & Medical Research Centre, Mumbai, Maharashtra, India.
⁷ Senior Director Medical Affairs, Biocon, Biologics Ltd, Bengaluru, Karnataka, India.

Abstract

Cyclosporine (CsA) is a calcineurin inhibitor that acts selectively on T cells. It has been used in dermatology since 1997 for its US Food and Drug Administration indication of psoriasis and off-label for various other inflammatory skin conditions, including atopic dermatitis, alopecia areata, urticaria, lichen planus and many others in pediatric, adults as well as in pregnant women. However, clinicians' preferences for management differ, which may have a bearing on the treatment selection. Hence, the purpose of this review is to outline the role of CsA in various skin conditions through consensus statement from six national experts in the field of dermatology.

Keywords: Alopecia areata; Cyclosporine (CsA); lichen planus; psoriasis; vitiligo.